Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-09)
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
오성용, 김성현, 이지현, Yunlin Zhang, Ruchi P Patel, 조형우, 윤덕현, 정성현, 최윤석, Marco Ruella, 이영하, 김종훈
Molecular cancer, 2023
4
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation
Incidence and risk factors of opportunistic infections after autologous stem cell transplantation: a nationwide, population-based cohort study in Korea
Relapse in patients with limited-stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow-up of a phase 2 study.
오성용, 김성용, 조석구, 이원식, 양덕환, 김효정, 박성규, 양재욱, 양석우
Cancer Medicine, 2022
9
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
오성용, Tycel Phillips, Henry Chan, Constantine S Tam, Alessandra Tedeschi, Patrick Johnston, Stephen Opat, 엄현석, Heather Allewelt, Jennifer C Stern, Ziwen Tan, William Novotny, Jane Huang, Judith Trotman
Blood Advances, 2022
10
Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study